[Escalated BEACOPP as an alternative in high risk Hodgkin lymphoma]. / Eskalowany BEACOPP jako alternatywa dla ABVD w chorobie Hodgkina o wysokim ryzyku.

ABSTRACT

Hodgkin Disease is one of the common lymphoma subtypes every year over 750 new cases are diagnosed in Poland. It is most frequent in young adults between 25 - 30 years of age. In a low risk cases prognosis is excellent, and the treatment may be limited to short chemotherapy consolidated by involved field radiotherapy. In high risk cases with a large tumor burden prognosis depends from the choice of the initial therapy. Results of 8 years experience with escalated BEACOPP in UJ CM Department of Hematology are summarized in the paper. Monitoring the early response in imaging studies, particularly in positron emission tomography, allows in the majority of cases to decrease the duration of intensive therapy, without loosing it's efficacy.